Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences Plc announced that the European Patent Office has recognized the patentability of its SIRT6 variant patent, marking a significant milestone in its intellectual property strategy. This development provides provisional protection across participating EPO member states, positioning Genflow to benefit from EU grant opportunities and strengthening its leverage in partnerships with pharmaceutical and biotech companies. The formal recognition of this patent underscores Genflow’s progress in securing its intellectual property and enhances its strategic position for future collaborations and funding.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020, is a UK-based biotechnology company with R&D facilities in Belgium. It focuses on pioneering gene therapies to slow down the aging process, aiming to promote longer and healthier lives. Genflow’s lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, and the company is conducting a 12-month proof-of-concept clinical trial in aged dogs. Future programs include exploring GF-1002’s potential in treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 7,902,415
Technical Sentiment Signal: Buy
See more insights into GENF stock on TipRanks’ Stock Analysis page.